top of page
img-logo-header.png
img-banner-desktop.png
img-banner-mobile.png

Biography

img-biography.jpg

Prof. Raymond R. Tjandrawinata, PhD, MS, MBA, FRSPH

Law and the Political Economy of Social Welfare

Education

Presents

Doctor of Juridical Science (Law) Candidate, expected graduation in 2028

Universitas Pelita Harapan, Jakarta, Indonesia


2025

Master of Law (LL.M)

IBLAM School of Law


Master of Advanced Studies in Theology

Domuni Universitas


1998

Master of Business Administration in Strategic Management

Ageno School of Business, San Francisco


1994-1996

Postdoctoral Research Fellowship in Molecular Pharmacology

Department of Medicine, University of California, San Francisco School of Medicine

Veterans Affairs Medical Center, San Francisco, CA.


1994

Doctor of Philosophy in Biochemistry

University of California, Riverside


1989

Master of Science in Biochemistry, concentration in Molecular Biology

University of California, Riverside


1987

Bachelor of Science in Chemistry and Biology

University of the Pacific, Stockton, CA

Research Area

A. Social Welfare Law:

  1. Health law reform: a political–economic analysis of Indonesia’s National Health Insurance (JKN), the Social Security Agency (BPJS), and national pharmaceutical self-reliance

  2. An adaptive patent law framework in the pharmaceutical sector: balancing exclusive rights and public access, with consideration of TRIPS and global policy trends

  3. Law as an instrument for distributing justice and strengthening Indonesia’s pharmaceutical sovereignty on the international stage


B. Economic Justification of Pharmaceutical and Biotechnological Research and Development:

  1. Innovation and Entrepreneurship

  2. Factors influencing pharmaceutical R&D spending

  3. Economics of biotechnological innovation


C. Molecular Pharmacology Studies of Chemical, Biological, and Naturally Derived Drugs for the Treatment of:

  1. Solid tumors: breast, prostate, cervical, liver, and lung cancer

  2. Metabolic diseases: diabetes, insulin resistance, dyslipidemia, and hypertension

  3. Cardiology diseases: atherosclerosis, congestive heart failure and arrhythmia

  4. Woman specific problems: premenstrual dysphoric disorder, osteoporosis

  5. Man-specific problems: benign prostatic hyperplasia and erectile dysfunctions

Professional Experience

January 2022 - Now

President Commissioner, PT Ferron Par Pharmaceuticals


July 2002 - Now

Director of Research and Business Development, Dexa Group


January 2011 - Now

Executive Director of Dexa Laboratories of Biomolecular Sciences (DLBS)


August 2005 - 2010

Director of Dexa Laboratories of Biomolecular Sciences (DLBS)


January 2001 - June 2002

Head of Medical Affairs and Business Development, PT Dexa Medica


May - December 2000

Medical and Training Manager, PT Dexa Medica


1998 - 2000

Senior Regional Medical Manager - Northern California


1996 - 1998

Regional Medical Associate - Northern California

SmithKline Beecham Pharmaceuticals, Pacific Coast Region, Sacramento, CA.

Academic Appointments

September 2022

Professor of Pharmaceutical Biotechnology, Atma Jaya University


January 2018 - December 2021

Head of Master's in Biotechnology program, Atma Jaya University


August 2016

Lecturer, Faculty of Biotechnology, Atma Jaya University


March 2012 - 2016

Adjunct Lecturer, Faculty of Biotechnology, Atma Jaya University


February 2012 – 2018

Advisory Council Member, Harvard Business Review


July 2011 – Now

Global Board Member of Academic Advisor, American Academy of Financial Management


May 2011 – Now

Advisory Council Member, International Management Consultants Board


1994 - 1996

Postdoctoral Fellow, Laboratory of Cell Growth and Differentiation, Department of Medicine, University of California, San Francisco School of Medicine

Veterans Affairs Medical Center, San Francisco, CA

Principal Investigator: Prof. Millie Hughes-Fulford, Ph.D.


Research Projects:

  • Biochemical pharmacology of drugs that inhibit prostaglandin synthesis

  • Molecular mechanisms by which prostaglandin E2 (PGE2) regulate normal and cancer cell growth

  • Transcriptional regulation and signal transduction of genes coding for enzyme/protein involved in the PGE2 synthesis and metabolism cyclo-oxygenase-2, cytoplasmic phospholipase A2, and low-density lipoprotein receptor

  • Mechanisms by which prostaglandins of the A series induce programmed cell death (apoptosis)


1994

Postdoctoral Fellow, Laboratory of Prof. Craig V. Byus, Ph.D., Division of Biomedical Sciences, University of California, Riverside


Research Projects:

  • Regulation of polyamine efflux in in vivo and in vitro models

  • Biochemistry of polyamine analogs


1989 - 1993

Graduate Research Associate, Laboratory of Prof. Craig V. Byus, Ph.D., Division of Biomedical Sciences, University of California, Riverside


Research Projects:

  • Characterization of polyamine metabolism and export during growth and quiescent periods of cell cycle

  • Animal two-stage carcinogenesis, investigation of tumor regression with dietary modification approach


1987 - 1989

Research Assistant, Laboratory of Prof. Richard A. Luben, Ph.D., Division of Biomedical Sciences, University of California, Riverside


Research Projects:

  • Screening of a cDNA library generated with the bacteriophage vector l-gt11 for parathyroid hormone receptor gene using monoclonal antibodies

bottom of page